Couldn't agree more, this drug has always been about giving patients time, delaying kidney failure and the need for dialysis. What this (and the previous) trials have shown is that this drug works - nothing has changed today except the share price!
I'm looking forward to further analysis concerning the placebo, the fact that it's a crossover study suggests something mysterious is going on - each patient acts as their own control, how did they improve 12% under placebo? If it's a legacy affect from DMX-200, then that would be very good news.
Good luck all
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-165
-
- There are more pages in this discussion • 463 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
53.3¢ |
Change
0.058(12.1%) |
Mkt cap ! $275.1M | |||
| Open | High | Low | Value | Volume |
| 47.5¢ | 54.0¢ | 47.5¢ | $2.311M | 4.500M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 93353 | 52.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.5¢ | 82176 | 5 |
View Market Depth
| Last trade - 13.00pm 16/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |